Hologic Inc. (HOLX) Earns Buy Rating from Evercore ISI
Other research analysts also recently issued research reports about the stock. Barclays PLC reissued a hold rating and set a $42.00 target price on shares of Hologic in a research report on Sunday, July 10th. Zacks Investment Research raised shares of Hologic from a hold rating to a buy rating and set a $43.00 target price on the stock in a research report on Wednesday, September 28th. Bank of America Corp. reissued a buy rating on shares of Hologic in a research report on Wednesday, June 22nd. Leerink Swann reissued an outperform rating and set a $46.00 target price on shares of Hologic in a research report on Monday, October 3rd. Finally, Jefferies Group reissued a buy rating and set a $42.00 target price on shares of Hologic in a research report on Tuesday, June 21st. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Hologic currently has an average rating of Buy and a consensus price target of $42.76.
Shares of Hologic (NASDAQ:HOLX) traded up 0.34% on Friday, reaching $38.45. 1,547,204 shares of the company were exchanged. The firm’s 50 day moving average price is $38.49 and its 200 day moving average price is $36.36. Hologic has a 52 week low of $31.84 and a 52 week high of $41.66. The stock has a market capitalization of $10.67 billion, a price-to-earnings ratio of 42.39 and a beta of 1.00.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.03. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The company earned $717.40 million during the quarter, compared to analyst estimates of $703.66 million. During the same quarter last year, the business posted $0.43 EPS. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. Equities research analysts anticipate that Hologic will post $1.94 EPS for the current year.
In related news, VP Karleen Marie Oberton sold 31,470 shares of the business’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $40.00, for a total value of $1,258,800.00. Following the completion of the transaction, the vice president now directly owns 17,005 shares in the company, valued at approximately $680,200. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Elaine Ullian sold 18,236 shares of the business’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $39.88, for a total transaction of $727,251.68. Following the completion of the transaction, the director now owns 42,898 shares of the company’s stock, valued at $1,710,772.24. The disclosure for this sale can be found here. 0.84% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Japan Co. Ltd boosted its position in Hologic by 3.1% in the first quarter. BlackRock Japan Co. Ltd now owns 313,303 shares of the company’s stock valued at $10,809,000 after buying an additional 9,312 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new stake in shares of Hologic during the first quarter valued at approximately $1,270,000. State Street Corp raised its stake in shares of Hologic by 26.4% in the first quarter. State Street Corp now owns 10,295,836 shares of the company’s stock valued at $355,210,000 after buying an additional 2,150,544 shares during the last quarter. UBS Group AG raised its stake in shares of Hologic by 5.8% in the first quarter. UBS Group AG now owns 794,751 shares of the company’s stock valued at $27,419,000 after buying an additional 43,652 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its stake in shares of Hologic by 1.2% in the first quarter. UBS Asset Management Americas Inc. now owns 637,813 shares of the company’s stock valued at $22,006,000 after buying an additional 7,810 shares during the last quarter. Hedge funds and other institutional investors own 94.51% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.